Gilbert N Clinton Ii, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park Dr, Benton, AR 72015 Phone: 501-776-6000 |
Dr. Carol N Eason, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1707 Scott Salem Rd, Benton, AR 72019 Phone: 501-316-1040 |
Dr. Daniel Earl Headrick, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park Dr, Benton, AR 72015 Phone: 501-776-6093 |
Benjamin T Mathews, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park Dr, Benton, AR 72015 Phone: 501-776-6000 |
Howell V Hill, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Park Dr, Benton, AR 72015 Phone: 501-776-6541 Fax: 501-574-7058 |
Stephen Michael Speck, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park Dr, Benton, AR 72015 Phone: 501-776-6100 |
News Archive
Despite a recent study finding that an increasing number of women who had cancer in one breast are opting to have the other breast removed, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology(TM) for Breast Cancer discourages prophylactic mastectomy in women except for those considered high risk.
MedPro Safety Products, Inc., a leading developer of transformational technologies that enable safer medication delivery and blood collection, has entered into a Joint Development Agreement (JDA) with Belgium-based Helvoet Pharma for the technical development and commercialization of MedPro's pre-filled safety syringe (PFSS).
A review of published scientific studies carried out by British researchers has revealed that people with low levels of the vitamins A and C were more likely to suffer from asthma.
A $2.2 million grant from the National Institutes of Health (NIH) will help researchers at the Methodist DeBakey Heart Center identify how weight loss and lifestyle changes affect the risk for heart disease in obese and diabetic patients, a rapidly-growing group in America.
Novartis announced today positive results of the first pivotal Phase III trial of ACZ885 in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease. The results, presented at the 2011 European Pediatric Rheumatology Congress in Bruges, Belgium, showed all primary and secondary endpoints of the study were met.
› Verified 7 days ago